Balancing Benefits and Risks: A Systematic Review and Meta-Analysis of ABO-Incompatible Kidney Transplantation.

Urol JSep 20, 2026 (epub)
Clinical ResearchNephrology

Fatemeh Pour-Rezagholi, Fariba Samadian, Mahsa Hoseini Chimeh et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the outcomes of ABO-incompatible versus ABO-compatible kidney transplantation, analyzing data from 63 studies involving 5,852 and 47,950 recipients, respectively. The study found that ABO-incompatible transplants had a higher risk of overall rejection (risk ratio = 1.28) and antibody-mediated rejection (risk ratio = 2.14), while 5-year patient survival was lower compared to ABO-compatible transplants (risk ratio = 1.62).

Key findings

  • ABO-incompatible transplantation had a higher risk of overall rejection (risk ratio = 1.28).
  • Antibody-mediated rejection was significantly higher in ABO-incompatible recipients (risk ratio = 2.14).
  • 5-year patient survival favored ABO-compatible transplants (risk ratio = 1.62).
  • Surgical complications and postoperative bleeding were markedly higher in ABO-incompatible recipients.

Why it matters

Understanding the risks and benefits of ABO-incompatible kidney transplantation is crucial for clinicians to make informed decisions regarding patient eligibility and management, particularly in balancing the need for expanded organ access against potential complications.

Source

PubMed · PMID 42773768

Published in Urol J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.